|
| Issue Date | Title | Author(s) |
| 2018 | Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC | Socinski, M. A.; Jotte, R. M.; Cappuzzo, F.; Orlandi, F.; Stroyakovskiy, D.; Nogami, N.; Rodríguez-Abreu, D.; Moro-Sibilot, D.; Thomas, C. A.; Barlesi, F.; Finley, G.; Kelsch, C.; Lee, A.; Coleman, S.; Deng, Y.; Shen, Y.; Kowanetz, M.; Lopez-Chavez, A.; Sandler, A.; Reck, M.; IMpower150 Study Grp | |
| 2018 | KEYNOTE-189 study of pembrolizumab (pembro) plus pemetrexed (pem) and platinum vs placebo plus pem and platinum for untreated, metastatic, nonsquamous NSCLC: Does choice of platinum affect outcomes? | Rodriguez Abreu, D.; Garassino, M. C.; Esteban, E.; Speranza, G.; Felip, E.; Domine, M.; Hochmair, M. J.; Powell, S.; Cheng, S. Y.S.; Bischoff, H. G.; Peled, N.; Hui, R.; Reck, M.; Garon, E. B.; Boyer, M.; Grossi, F.; Jennens, R.; Yang, J.; Pietanza, M. C.; Gadgeel, S. | |
| 2019 | Evaluation of TMB in KEYNOTE-189: Pembrolizumab Plus Chemotherapy vs Placebo Plus Chemotherapy for Nonsquamous NSCLC | Garassino, M.; Rodriguez-Abreu, D.; Gadgeel, S.; Esteban, E.; Felip, E.; Speranza, G.; Reck, M.; Hui, R.; Boyer, M.; Cristescu, R.; Aurora-Garg, D.; Albright, A.; Loboda, A.; Kobie, J.; Lunceford, J.; Ayers, M.; Lubiniecki, G.; Piperdi, B.; Pietanza, M. C.; Garon, E. | |
| 2019 | Pembrolizumab plus Pemetrexed-Platinum for Patients with Metastatic Nonsquamous NSCLC and Liver or Brain Metastases: Results from KEYNOTE-189 | Garassino, M. C.; Gadgeel, S.; Esteban, E.; Felip, E.; Speranza, G.; De Angelis, F.; Domine, M.; Clingan, P.; Hochmair, M. J.; Powell, S. F.; Cheng, S. Y. -S.; Bischoff, H. G.; Peled, N.; Grossi, F.; Jennens, R. R.; Reck, M.; Hui, R.; Garon, E. B.; Boyer, M.; Rubio-Viqueira, B.; Novello, S.; Kurata, T.; Gray, J. E.; Cardellino, A.; Yang, J.; Pietanza, M. C.; Rodriguez-Abreu, D. | |
| 2019 | KEYNOTE-189: OS Update and Progression After the Next Line of Therapy (PFS2) with Pembrolizumab plus Chemotherapy for Metastatic Nonsquamous NSCLC | Gadgeel, S.; Garassino, M. C.; Esteban, E.; Speranza, G.; Felip, E.; Hochmair, M. J.; Powell, S.; Cheng, S. Y. -S.; Bischoff, H. G.; Peled, N.; Hui, R.; Reck, M.; Kurata, T.; Garon, E. B.; Boyer, M.; Yang, J.; Pietanza, M. C.; Rodriguez-Abreu, D. | |
| 2019 | KRAS mutational status and efficacy in KEYNOTE-189: Pembrolizumab (pembro) plus chemotherapy (chemo) vs placebo plus chemo as first-line therapy for metastatic non-squamous NSCLC | Gadgeel, S.; Rodriguez-Abreu, D.; Felip, E.; Esteban, E.; Speranza, G.; Reck, M.; Hui, R.; Boyer, M.; Garon, E. B.; Horinouchi, H.; Cristescu, R.; Aurora-Garg, D.; Lunceford, J.; Kobie, J.; Ayers, M.; Piperdi, B.; Pietanza, M. C.; Garassino, M. C. | |